MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

PHR.US

8.74

-3.53%↓

Search

Ovid therapeutics Inc

Fechado

SetorSaúde

2.6 0.39

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.49

Máximo

2.63

Indicadores-chave

By Trading Economics

Rendimento

22M

9.7M

Vendas

586K

718K

Margem de lucro

1,345.822

Funcionários

23

EBITDA

-152K

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+126.09% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

209M

347M

Abertura anterior

2.21

Fecho anterior

2.6

Sentimento de Notícias

By Acuity

50%

50%

151 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de abr. de 2026, 17:26 UTC

Notícias Principais

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 de abr. de 2026, 23:55 UTC

Conversa de Mercado

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 de abr. de 2026, 23:47 UTC

Conversa de Mercado
Notícias Principais

Market Talk Roundup: Latest on U.S. Politics

7 de abr. de 2026, 23:47 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 de abr. de 2026, 23:44 UTC

Conversa de Mercado
Notícias Principais

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 de abr. de 2026, 23:42 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

7 de abr. de 2026, 23:42 UTC

Conversa de Mercado

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 de abr. de 2026, 23:37 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 de abr. de 2026, 23:15 UTC

Conversa de Mercado
Notícias Principais

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 de abr. de 2026, 23:04 UTC

Notícias Principais

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 de abr. de 2026, 23:04 UTC

Notícias Principais

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 de abr. de 2026, 23:03 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de abr. de 2026, 23:03 UTC

Conversa de Mercado

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 de abr. de 2026, 23:01 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 de abr. de 2026, 22:58 UTC

Notícias Principais

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 de abr. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

7 de abr. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de abr. de 2026, 19:45 UTC

Conversa de Mercado

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 de abr. de 2026, 19:17 UTC

Notícias Principais

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 de abr. de 2026, 19:16 UTC

Conversa de Mercado

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 de abr. de 2026, 19:07 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

7 de abr. de 2026, 19:07 UTC

Conversa de Mercado

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 de abr. de 2026, 18:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 de abr. de 2026, 18:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 de abr. de 2026, 18:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 de abr. de 2026, 18:24 UTC

Notícias Principais

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 de abr. de 2026, 17:08 UTC

Conversa de Mercado

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 de abr. de 2026, 16:21 UTC

Notícias Principais

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

126.09% parte superior

Previsão para 12 meses

Média 5.2 USD  126.09%

Máximo 7 USD

Mínimo 4 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

151 / 349 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat